US6025372A
(en)
*
|
1997-04-04 |
2000-02-15 |
Merck & Co., Inc. |
Somatostatin agonists
|
GB9819860D0
(en)
|
1998-09-12 |
1998-11-04 |
Zeneca Ltd |
Chemical compounds
|
WO2000018764A1
(en)
*
|
1998-09-30 |
2000-04-06 |
Merck Sharp & Dohme Limited |
Benzimidazolinyl piperidines as cgrp ligands
|
DE19911039A1
(de)
*
|
1999-03-12 |
2000-09-14 |
Boehringer Ingelheim Pharma |
Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
US6313097B1
(en)
|
1999-03-02 |
2001-11-06 |
Boehringer Ingelheim Pharma Kg |
Antagonists of calcitonin gene-related peptide
|
US6387932B1
(en)
|
1999-06-25 |
2002-05-14 |
Merck & Co., Inc. |
Somatostatin agonists
|
US6521609B1
(en)
|
1999-08-10 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
|
DE19937304C2
(de)
*
|
1999-08-10 |
2003-08-21 |
Boehringer Ingelheim Pharma |
Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
|
DE19952147A1
(de)
|
1999-10-29 |
2001-05-03 |
Boehringer Ingelheim Pharma |
Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
DE19952146A1
(de)
|
1999-10-29 |
2001-06-07 |
Boehringer Ingelheim Pharma |
Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
AU778810B2
(en)
|
1999-11-04 |
2004-12-23 |
Ortho-Mcneil Pharmaceutical, Inc. |
Nonpeptide substituted benzothiazepines as vasopressin antagonists
|
DE19963868A1
(de)
*
|
1999-12-30 |
2001-07-12 |
Boehringer Ingelheim Pharma |
Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
RU2002126554A
(ru)
|
2000-03-06 |
2004-03-20 |
Акадиа Фармасьютикалз, Инк. (Us) |
Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
|
AR033517A1
(es)
*
|
2000-04-08 |
2003-12-26 |
Astrazeneca Ab |
Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
|
US6653478B2
(en)
|
2000-10-27 |
2003-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
|
MXPA03007857A
(es)
*
|
2001-03-01 |
2004-05-24 |
Emisphere Tech Inc |
Compuestos y composiciones para entregar agentes activos.
|
GB0108876D0
(en)
*
|
2001-04-09 |
2001-05-30 |
Novartis Ag |
Organic Compounds
|
SI1598339T1
(sl)
*
|
2001-04-18 |
2009-12-31 |
Euro Celtique Sa |
Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine
|
US7307090B2
(en)
|
2001-07-02 |
2007-12-11 |
Astrazeneca Ab |
Piperidine derivatives useful as modulators of chemokine receptor activity
|
US7115607B2
(en)
|
2001-07-25 |
2006-10-03 |
Amgen Inc. |
Substituted piperazinyl amides and methods of use
|
US6977264B2
(en)
*
|
2001-07-25 |
2005-12-20 |
Amgen Inc. |
Substituted piperidines and methods of use
|
DE10139410A1
(de)
*
|
2001-08-17 |
2003-02-27 |
Boehringer Ingelheim Pharma |
Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
|
US20030181462A1
(en)
*
|
2001-08-17 |
2003-09-25 |
Boehringer Ingelheim Pharma Kg |
Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
|
GB0120461D0
(en)
|
2001-08-22 |
2001-10-17 |
Astrazeneca Ab |
Novel compounds
|
GB0122503D0
(en)
|
2001-09-18 |
2001-11-07 |
Astrazeneca Ab |
Chemical compounds
|
ATE466014T1
(de)
|
2001-12-28 |
2010-05-15 |
Acadia Pharm Inc |
Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
|
US6900317B2
(en)
|
2002-02-19 |
2005-05-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
|
DE10206770A1
(de)
*
|
2002-02-19 |
2003-08-28 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
|
US20040014679A1
(en)
*
|
2002-02-20 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
|
US7026312B2
(en)
|
2002-03-14 |
2006-04-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
SE0200843D0
(sv)
|
2002-03-19 |
2002-03-19 |
Astrazeneca Ab |
Chemical compounds
|
SE0200844D0
(sv)
|
2002-03-19 |
2002-03-19 |
Astrazeneca Ab |
Chemical compounds
|
US7842808B2
(en)
*
|
2002-06-05 |
2010-11-30 |
Bristol-Myers Squibb Company |
Anti-migraine spirocycles
|
NZ537315A
(en)
|
2002-06-05 |
2006-04-28 |
Bristol Myers Squibb Co |
Calcitonin gene related peptide receptor antagonists
|
US7220862B2
(en)
|
2002-06-05 |
2007-05-22 |
Bristol-Myers Squibb Company |
Calcitonin gene related peptide receptor antagonists
|
DE10227294A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
|
US20040076587A1
(en)
*
|
2002-06-19 |
2004-04-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical composition for intranasal administration containing a CGRP antagonist
|
MXPA04012893A
(es)
|
2002-06-24 |
2005-03-31 |
Acadia Pharm Inc |
Derivados de piperidina n-substituidos como agentes receptores de serotonina.
|
US7538222B2
(en)
|
2002-06-24 |
2009-05-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
US7253186B2
(en)
|
2002-06-24 |
2007-08-07 |
Carl-Magnus Andersson |
N-substituted piperidine derivatives as serotonin receptor agents
|
GB0218326D0
(en)
*
|
2002-08-07 |
2002-09-11 |
Glaxo Group Ltd |
Compounds
|
US7414057B2
(en)
*
|
2002-09-11 |
2008-08-19 |
Merck & Co., Inc. |
Piperazine urea derivatives as melanocortin-4 receptor agonists
|
US7595312B2
(en)
|
2002-10-25 |
2009-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
|
DE10250082A1
(de)
|
2002-10-25 |
2004-05-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10300973A1
(de)
*
|
2003-01-14 |
2004-07-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
JP5184777B2
(ja)
|
2003-01-16 |
2013-04-17 |
アカディア ファーマシューティカルズ,インコーポレーテッド |
神経変性疾患用治療薬としての選択的セロトニン2a/2c受容体インバースアゴニスト
|
SE0300957D0
(sv)
|
2003-04-01 |
2003-04-01 |
Astrazeneca Ab |
Chemical compounds
|
US20050043247A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
|
US20050042179A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
US20050042178A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
|
US20050042180A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
|
US20050065094A1
(en)
|
2003-09-05 |
2005-03-24 |
Boehringer Ingelheim International Gmbh |
Use of telmisartan for the prevention and treatment of vascular headache
|
KR100661118B1
(ko)
*
|
2003-11-12 |
2006-12-26 |
주식회사 엘지생명과학 |
멜라노코틴 수용체의 항진제
|
MXPA06005687A
(es)
|
2003-11-20 |
2006-08-17 |
Janssen Pharmaceutica Nv |
2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
|
MXPA06005686A
(es)
|
2003-11-20 |
2006-08-17 |
Janssen Pharmaceutica Nv |
2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
|
TW200524601A
(en)
*
|
2003-12-05 |
2005-08-01 |
Bristol Myers Squibb Co |
Heterocyclic anti-migraine agents
|
UA81563C2
(en)
|
2003-12-05 |
2008-01-10 |
Bristol Myers Squibb Co |
Antagonists of calcitonin gene-related peptide receptors
|
SG151249A1
(en)
*
|
2003-12-05 |
2009-04-30 |
Janssen Pharmaceutica Nv |
6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
DE102004006893A1
(de)
*
|
2004-02-12 |
2005-09-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
|
US20050192230A1
(en)
*
|
2004-02-12 |
2005-09-01 |
Boehringer Ingelheim International Gambh |
Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
TW200533398A
(en)
|
2004-03-29 |
2005-10-16 |
Bristol Myers Squibb Co |
Novel therapeutic agents for the treatment of migraine
|
US7279471B2
(en)
|
2004-04-15 |
2007-10-09 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
US20050282857A1
(en)
*
|
2004-04-15 |
2005-12-22 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
DE102004018795A1
(de)
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102004018794A1
(de)
*
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102004018796A1
(de)
*
|
2004-04-15 |
2005-11-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7547694B2
(en)
*
|
2004-04-15 |
2009-06-16 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
US20050233980A1
(en)
*
|
2004-04-20 |
2005-10-20 |
Boehringer Ingelheim International Gmbh |
CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
|
DE102004019492A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7696195B2
(en)
*
|
2004-04-22 |
2010-04-13 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
US7820695B2
(en)
|
2004-05-21 |
2010-10-26 |
Acadia Pharmaceuticals, Inc. |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
JP4852540B2
(ja)
*
|
2004-06-30 |
2012-01-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Parp阻害剤としてのフタラジン誘導体
|
AU2005259190B2
(en)
|
2004-06-30 |
2011-05-12 |
Janssen Pharmaceutica N.V. |
Quinazolinedione derivatives as PARP inhibitors
|
CN1976906B
(zh)
*
|
2004-06-30 |
2010-09-01 |
詹森药业有限公司 |
用作parp抑制剂的取代2-烷基喹唑啉酮衍生物
|
US7790899B2
(en)
|
2004-09-27 |
2010-09-07 |
Acadia Pharmaceuticals, Inc. |
Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
|
CA2580136C
(en)
|
2004-09-27 |
2015-08-18 |
Acadia Pharmaceuticals Inc. |
Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
|
US7384930B2
(en)
*
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
US7384931B2
(en)
*
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
US7449586B2
(en)
|
2004-12-03 |
2008-11-11 |
Bristol-Myers Squibb Company |
Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
|
DE102004063752A1
(de)
*
|
2004-12-29 |
2006-07-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
|
DE102004063755A1
(de)
*
|
2004-12-29 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
|
DE102004063753A1
(de)
*
|
2004-12-29 |
2006-07-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
|
US7491717B2
(en)
*
|
2005-03-23 |
2009-02-17 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
EP1770091A1
(de)
*
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7439237B2
(en)
*
|
2005-04-15 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
EP1912941B1
(en)
|
2005-07-21 |
2012-11-14 |
AstraZeneca AB |
Piperidine derivatives
|
DE102005038831A1
(de)
*
|
2005-08-17 |
2007-02-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7834007B2
(en)
|
2005-08-25 |
2010-11-16 |
Bristol-Myers Squibb Company |
CGRP antagonists
|
DE102005042828A1
(de)
*
|
2005-09-09 |
2007-03-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGPR-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
EP1770087A1
(de)
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
EP1770086A1
(de)
*
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102005050892A1
(de)
*
|
2005-10-21 |
2007-04-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
EP3045182B1
(en)
|
2005-11-14 |
2018-03-07 |
Teva Pharmaceuticals International GmbH |
Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache
|
US7851464B2
(en)
*
|
2005-11-18 |
2010-12-14 |
Merck Sharp & Dohme Corp. |
Spirolactam aryl CGRP receptor antagonists
|
US7601844B2
(en)
*
|
2006-01-27 |
2009-10-13 |
Bristol-Myers Squibb Company |
Piperidinyl derivatives as modulators of chemokine receptor activity
|
WO2007115805A2
(en)
*
|
2006-04-05 |
2007-10-18 |
European Molecular Biology Laboratory (Embl) |
Aurora kinase inhibitors
|
DE102006017827A1
(de)
|
2006-04-13 |
2007-10-18 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue kristalline Verbindungen
|
TW200813018A
(en)
|
2006-06-09 |
2008-03-16 |
Astrazeneca Ab |
Novel compounds
|
WO2008079945A2
(en)
*
|
2006-12-20 |
2008-07-03 |
University Of South Florida |
Rock inhibitors and uses thereof
|
SI2134691T1
(sl)
|
2007-03-08 |
2012-06-29 |
Janssen Pharmaceutica Nv |
Derivati kvinolina kot PARP in TANK inhibitorji
|
PL2134330T3
(pl)
|
2007-03-19 |
2013-10-31 |
Acadia Pharm Inc |
Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
|
US8119661B2
(en)
|
2007-09-11 |
2012-02-21 |
Astrazeneca Ab |
Piperidine derivatives and their use as muscarinic receptor modulators
|
WO2009053373A1
(en)
|
2007-10-26 |
2009-04-30 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as parp inhibitors
|
EP3441087A1
(en)
|
2008-03-04 |
2019-02-13 |
Teva Pharmaceuticals International GmbH |
Methods of treating chronic pain
|
BRPI0908276B8
(pt)
|
2008-03-04 |
2021-05-25 |
Labrys Biologics Inc |
uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
|
CA2716726C
(en)
|
2008-03-27 |
2017-01-24 |
Janssen Pharmaceutica Nv |
Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
|
WO2009118384A1
(en)
|
2008-03-27 |
2009-10-01 |
Janssen Pharmaceutica Nv |
Quinazolinone derivatives as tubulin polymerization inhibitors
|
TWI433838B
(zh)
|
2008-06-25 |
2014-04-11 |
必治妥美雅史谷比公司 |
作為趨化因子受體活性調節劑之六氫吡啶衍生物
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
EP2470207A1
(en)
|
2009-08-28 |
2012-07-04 |
Rinat Neuroscience Corporation |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
US8642622B2
(en)
|
2010-06-16 |
2014-02-04 |
Bristol-Myers Squibb Company |
Piperidinyl compound as a modulator of chemokine receptor activity
|
AR086515A1
(es)
|
2011-05-20 |
2013-12-18 |
Alderbio Holdings Llc |
Uso de anticuerpos o fragmentos de anticuerpos anti-cgrp o anti-cgrp-r para tratar o prevenir las formas cronicas y agudas de la diarrea
|
CA3079978A1
(en)
|
2011-05-20 |
2012-11-29 |
Alderbio Holdings Llc |
Anti-cgrp compositions and use thereof
|
CN108014334B
(zh)
|
2011-05-20 |
2021-11-30 |
H.伦德贝克公司 |
抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
|
JP5988087B2
(ja)
*
|
2012-06-07 |
2016-09-07 |
Dic株式会社 |
化合物の製造方法
|
WO2014102592A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
|
UA123759C2
(uk)
|
2014-03-21 |
2021-06-02 |
Тева Фармасьютікалз Інтернешнл Гмбх |
Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
EP3325444B1
(en)
|
2015-07-20 |
2021-07-07 |
Acadia Pharmaceuticals Inc. |
Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
|
GB201519195D0
(en)
|
2015-10-30 |
2015-12-16 |
Heptares Therapeutics Ltd |
CGRP Receptor Antagonists
|
GB201519196D0
(en)
|
2015-10-30 |
2015-12-16 |
Heptares Therapeutics Ltd |
CGRP Receptor Antagonists
|
GB201519194D0
(en)
|
2015-10-30 |
2015-12-16 |
Heptares Therapeutics Ltd |
CGRP receptor antagonists
|
US10953000B2
(en)
|
2016-03-25 |
2021-03-23 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome P450 modulators
|
WO2017165635A1
(en)
|
2016-03-25 |
2017-09-28 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome p450 modulators
|
CA3036632A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating refractory migraine
|
WO2018118626A1
(en)
|
2016-12-20 |
2018-06-28 |
Acadia Pharmaceuticals Inc. |
Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
|
WO2018200977A1
(en)
|
2017-04-28 |
2018-11-01 |
Acadia Pharmaceuticals Inc. |
Pimavanserin for treating impulse control disorder
|
EP3675827A1
(en)
|
2017-08-30 |
2020-07-08 |
Acadia Pharmaceuticals Inc. |
Formulations of pimavanserin
|
CA3123237A1
(en)
|
2019-01-08 |
2020-07-16 |
H. Lundbeck A/S |
Acute treatment and rapid treatment of headache using anti-cgrp antibodies
|
CA3212151A1
(en)
|
2021-03-02 |
2022-09-09 |
Cgrp Diagnostics Gmbh |
Treatment and/or reduction of occurrence of migraine
|
WO2023026205A1
(en)
|
2021-08-24 |
2023-03-02 |
Cgrp Diagnostics Gmbh |
Preventative treatment of migraine
|
WO2024100171A1
(en)
|
2022-11-11 |
2024-05-16 |
Boehringer Ingelheim International Gmbh |
Olcegepant for treating sepsis
|